Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium

BMC Research Notes

Volumn 2, Issue , 2009, Pages

  Cortes Perez, Naima G ^a   Kharrat, Pascale ^a   Langella, Philippe ^a   Bermdez Humarán, Luis G ^a  

^a CEMAGREF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS); HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; LACTOCOCCUS; LACTOCOCCUS LACTIS; MIRIDAE;

EID: 71949094593     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-2-167     Document Type: Article

References (33)

1. Human papillomavirus and cervical cancer. M Schiffman PE Castle J Jeronimo AC Rodriguez S Wacholder, Lancet 2007 8 890 907 10.1016/S0140-6736(07) 61416-0 (Pubitemid 47371147)
2. Natural history and epidemiology of HPV infection and cervical cancer. X Castellsagué Gynecol Oncol 2008 110 4 7 10.1016/j.ygyno.2008.07.045 18760711
3. A controlled trial of a human papillomavirus type 16 vaccine. LA Koutsky KA Ault CM Wheeler DR Brown E Barr FB Alvarez LM Chiacchierini KU Jansen Proof of Principle Study Investigators, N Engl J Med 2002 21 1645 1651 10.1056/NEJMoa020586 (Pubitemid 35340782)
4. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. JT Schiller X Castellsagué LL Villa A Hildesheim, Vaccine 2008 19 53 61 10.1016/j.vaccine.2008.06.002
5. Mucosal vaccines: the promise and the challenge. MR Neutra PA Kozlowski, Nat Rev Immunol 2006 6 148 158 10.1038/nri1777 16491139
6. Optimism over vaccines administered via mucosal surfaces. MM Levine G Dougan, Lancet 1998 9 1375 1376 10.1016/S0140-6736(05)79439-3 (Pubitemid 28209992)
7. Recent advances in the use of Lactococcus lactis as live recombinant vector for the development of new safe mucosal vaccines. LG Bermdez-Humarn G Corthier P Langella, Recent Res Dev Microbiol 2004 8 147 160
8. Potential and opportunities for use of recombinant lactic acid bacteria in human health. S Hanniffy U Wiedermann A Repa A Mercenier C Daniel J Fioramonti H Tlaskolova H Kozakova H Israelsen S Madsen A Vrang P Hols J Delcour P Bron M Kleerebezem J Wells, Adv Appl Microbiol 2004 56 1 64 15566975
9. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. JM Wells A Mercenier, Nat Rev Microbiol 2008 6 349 62 10.1038/nrmicro1840 18345021
10. Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. LG Bermdez-Humarn P Langella A Miyoshi A Gruss RT Guerra R Montes de Oca-Luna Y Le Loir, Appl Environ Microbiol 2002 68 917 22 10.1128/AEM.68.2.917- 922.2002 11823236
11. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. LG Bermdez-Humarn NG Cortes-Perez Y Le Loir JM Alcocer-Gonzlez RS Tamez-Guerra RM de Oca-Luna P Langella, J Med Microbiol 2004 53 427 433 10.1099/jmm.0.05472-0 15096553
12. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. NG Cortes-Perez LG Bermdez-Humarn Y Le Loir C Rodriguez-Padilla A Gruss O Saucedo-Crdenas P Langella R Montes-de-Oca-Luna, FEMS Microbiol Lett 2003 5 37 42 10.1016/S0378-1097(03)00778-X (Pubitemid 37505000)
13. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. LG Bermdez-Humarn NG Cortes-Perez F Lefèvre V Guimares S Rabot JM Alcocer-Gonzalez JJ Gratadoux C Rodriguez-Padilla RS Tamez-Guerra G Corthier A Gruss P Langella, J Immunol 2005 175 7297 7302 16301635
14. Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. KA Aires AM Cianciarullo SM Carneiro LL Villa E Boccardo G Pérez-Martinez I Perez-Arellano ML Oliveira PL Ho, Appl Environ Microbiol 2006 72 745 52 10.1128/AEM.72.1.745-752.2006 16391114
15. Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. HJ Cho HJ Shin IK Han WW Jung YB Kim D Sul YK Oh, Vaccine 2007 25 8049 57 10.1016/j.vaccine.2007.09.024 17936447
16. Current prophylactic and therapeutic uses of a recombinant Lactococcus lactis strain secreting biologically active interleukin-12. LG Bermdez-Humarn NG Cortes-Perez S Ah-Leung F Lefèvre G Yang Q Pang C Wu Y Zeng K Adel-Patient P Langella, J Mol Microbiol Biotechnol 2008 14 80 89 10.1159/000106086 17957114
17. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. R Kirnbauer F Booy N Cheng DR Lowy JT Schiller, Proc Natl Acad Sci USA 1992 89 12180 12184 10.1073/pnas.89.24.12180 1334560
18. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. D Nardelli-Haefliger RB Roden J Benyacoub R Sahli JP Kraehenbuhl JT Schiller P Lachat A Potts P De Grandi, Infect Immun 1997 65 3328 3336 9234794
19. Yeast coexpression of human papillomavirus types 6 and 16 capsid proteins. DT Buonamassa CE Greer S Capo TS Yen CL Galeotti G Bensi, Virology 2002 15 335 344 10.1006/viro.2001.1289 (Pubitemid 34928855)
20. Production of human papillomavirus type 16 virus-like particles in transgenic plants. S Biemelt U Sonnewald P Galmbacher L Willmitzer M Müller, J Virol 2003 77 9211 9220 10.1128/JVI.77.17.9211-9220.2003 12915537
21. Protein secretion in Lactococcus lactis: an efficient way to increase the overall heterologous protein production. Y Le Loir V Azevedo SC Oliveira DA Freitas A Miyoshi LG Bermdez-Humarn S Nouaille LA Ribeiro S Leclercq JE Gabriel VD Guimaraes MN Oliveira C Charlier M Gautier P Langella, Microb Cell Fact 2005 4 2 10.1186/1475-2859-4-2 15631634
22. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. EF Dunne SDE Datta L Markowitz, Cancer 2008 113 2995 3003 18980283
23. Correlating immunity with protection for HPV infection. I Frazer, Int J Infect Dis 2007 11 10 16 10.1016/S1201-9712(07)60016-2 18162240
24. Efficient plasmid mobilization by pIP501 in Lactococcus lactis subsp. lactis. P Langella Y Le Loir SD Ehrlich A Gruss, J Bacteriol 1993 175 5806 5813 8376328
25. Cloning, expression in Escherichia coli and characterization of usp45, a gene encoding a highly secreted protein from Lactococcus lactis MG1363. M van Asseldonk G Rutten M Oteman RJ Siezen WM de Vos G Simons, Gene 1990 30 155 160 10.1016/0378-1119(90)90428-T
26. Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. PG de Ruyter OP Kuipers WM de Vos, Appl Environ Microbiol 1996 62 3662 3667 8837421
27. Quorum sensing-controlled gene expression in lactic acid bacteria. OP Kuipers PG de Ruyter M Kleerebezen WM de Vos, J Biotechnol 1998 64 15 21 10.1016/S0168-1656(98)00100-X (Pubitemid 29027781)
28. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. ND Christensen J Dillner C Eklund JJ Carter GC Wipf CA Reed NM Cladel DA Galloway, Virology 1996 223 174 184 10.1006/viro.1996.0466 8806551
29. Plasmid complements of Streptococcus lactis NCDO 712 and other lactic acid streptococci after protoplast-induced curing. MJ Gasson, J Bacteriol 1983 154 1 9 6403500
30. TJ Gibson, PhD thesis University of Cambridge, Cambridge, England 1984
31. Studies towards the potential of poliovirus as a vector for the expression of HPV 16 virus-like-particles. FJ van Kuppeveld A de Jong HB Dijkman R Andino WJ Melchers, FEMS Immunol Med Microbiol 2002 15 201 208 10.1016/S0928-8244(02)00396-6 (Pubitemid 35335520)
32. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. I Mierau M Kleerebezem, Appl Microbiol Biotechnol 2005 68 705 17 10.1007/s00253-005-0107-6 16088349
33. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. L Steidler S Neirynck N Huyghebaert V Snoeck A Vermeire B Goddeeris E Cox JP Remon E Remaut, Nat Biotechnol 2003 21 785 9 10.1038/nbt840 12808464